Skip to main
TBI
TBI logo

TrueBlue (TBI) Stock Forecast & Price Target

TrueBlue (TBI) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

TrueBlue Inc. reported a year-over-year revenue increase of 2%, indicating resilience in its business model, primarily driven by strong commercial performance that achieved double-digit growth. This growth was complemented by a significant improvement in the adjusted EBITDA margin, which rose by 50 basis points to 0.7%, reflecting the effectiveness of strategic cost actions taken by the company. Although the revenue growth fell slightly below the midpoint guidance, the company's underlying operational efficiencies and strong segment performance, particularly in PeopleReady, contribute to a positive long-term outlook for the stock.

Bears say

TrueBlue Inc. experienced a significant decline in its adjusted EBITDA margin, which fell 320 basis points year-over-year to 5.2%, primarily due to lower operating leverage resulting from a decrease in organic revenues. The PeopleReady segment, responsible for the majority of the company's revenue, reported a 5% year-over-year decline, contrasting with management's midpoint guidance of a 3% decline, indicating continued weakness across various client verticals. Additionally, TrueBlue reported an adjusted loss per share of $(0.07) for the second quarter, reinforcing concerns about its financial performance in a challenging market environment.

TrueBlue (TBI) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TrueBlue and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TrueBlue (TBI) Forecast

Analysts have given TrueBlue (TBI) a Buy based on their latest research and market trends.

According to 1 analysts, TrueBlue (TBI) has a Buy consensus rating as of Nov 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TrueBlue (TBI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.